Literature DB >> 22034206

Clinical trials in the era of personalized oncology.

Michael L Maitland1, Richard L Schilsky.   

Abstract

The rapid pace of discoveries in tumor biology, imaging technology, and human genetics hold promise for an era of personalized oncology care. The successful development of a handful of new targeted agents has generated much hope and hype about the delivery of safer and more effective new treatments for cancer. The design and conduct of clinical trials has not yet adjusted to a new era of personalized oncology and so we are more in transition to that era than in it. With the development of treatments for breast cancer as a model, we review the approaches to clinical trials and the development of novel therapeutics in the prior era of population oncology, the current transitional era, and the future era of personalized oncology.
Copyright © 2011 American Cancer Society, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22034206      PMCID: PMC3218227          DOI: 10.3322/caac.20135

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN: 0007-9235            Impact factor:   508.702


  91 in total

Review 1.  Can the pharmaceutical industry reduce attrition rates?

Authors:  Ismail Kola; John Landis
Journal:  Nat Rev Drug Discov       Date:  2004-08       Impact factor: 84.694

2.  Why we're losing the war on cancer (and how to win it).

Authors:  Clifton Leaf
Journal:  Fortune       Date:  2004-03-22

3.  Phase II oncology trials: let's be positive.

Authors:  Mark J Ratain
Journal:  Clin Cancer Res       Date:  2005-08-15       Impact factor: 12.531

Review 4.  Clinical trial designs for predictive marker validation in cancer treatment trials.

Authors:  Daniel J Sargent; Barbara A Conley; Carmen Allegra; Laurence Collette
Journal:  J Clin Oncol       Date:  2005-03-20       Impact factor: 44.544

5.  Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28.

Authors:  Eleftherios P Mamounas; John Bryant; Barry Lembersky; Louis Fehrenbacher; Scot M Sedlacek; Bernard Fisher; D Lawrence Wickerham; Greg Yothers; Atilla Soran; Norman Wolmark
Journal:  J Clin Oncol       Date:  2005-05-16       Impact factor: 44.544

6.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

7.  Cancer trial enrollment after state-mandated reimbursement.

Authors:  C P Gross; V Murthy; Y Li; A D Kaluzny; H M Krumholz
Journal:  J Natl Cancer Inst       Date:  2004-07-21       Impact factor: 13.506

8.  A gene-expression signature as a predictor of survival in breast cancer.

Authors:  Marc J van de Vijver; Yudong D He; Laura J van't Veer; Hongyue Dai; Augustinus A M Hart; Dorien W Voskuil; George J Schreiber; Johannes L Peterse; Chris Roberts; Matthew J Marton; Mark Parrish; Douwe Atsma; Anke Witteveen; Annuska Glas; Leonie Delahaye; Tony van der Velde; Harry Bartelink; Sjoerd Rodenhuis; Emiel T Rutgers; Stephen H Friend; René Bernards
Journal:  N Engl J Med       Date:  2002-12-19       Impact factor: 91.245

9.  Participation in cancer clinical trials: race-, sex-, and age-based disparities.

Authors:  Vivek H Murthy; Harlan M Krumholz; Cary P Gross
Journal:  JAMA       Date:  2004-06-09       Impact factor: 56.272

10.  Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

Authors:  I Craig Henderson; Donald A Berry; George D Demetri; Constance T Cirrincione; Lori J Goldstein; Silvana Martino; James N Ingle; M Robert Cooper; Daniel F Hayes; Katherine H Tkaczuk; Gini Fleming; James F Holland; David B Duggan; John T Carpenter; Emil Frei; Richard L Schilsky; William C Wood; Hyman B Muss; Larry Norton
Journal:  J Clin Oncol       Date:  2003-03-15       Impact factor: 44.544

View more
  27 in total

Review 1.  Predicting outcomes in radiation oncology--multifactorial decision support systems.

Authors:  Philippe Lambin; Ruud G P M van Stiphout; Maud H W Starmans; Emmanuel Rios-Velazquez; Georgi Nalbantov; Hugo J W L Aerts; Erik Roelofs; Wouter van Elmpt; Paul C Boutros; Pierluigi Granone; Vincenzo Valentini; Adrian C Begg; Dirk De Ruysscher; Andre Dekker
Journal:  Nat Rev Clin Oncol       Date:  2012-11-20       Impact factor: 66.675

2.  Trastuzumab and congestive heart failure: what can we learn from use in the community?

Authors:  Ann M Geiger
Journal:  J Natl Cancer Inst       Date:  2012-09-05       Impact factor: 13.506

Review 3.  [Big data in imaging].

Authors:  Philipp Sewerin; Benedikt Ostendorf; Axel J Hueber; Arnd Kleyer
Journal:  Z Rheumatol       Date:  2018-04       Impact factor: 1.372

4.  Vol-PACT: A Foundation for the NIH Public-Private Partnership That Supports Sharing of Clinical Trial Data for the Development of Improved Imaging Biomarkers in Oncology.

Authors:  Laurent Dercle; Dana E Connors; Ying Tang; Stacey J Adam; Mithat Gönen; Patrick Hilden; Sanja Karovic; Michael Maitland; Chaya S Moskowitz; Gary Kelloff; Binsheng Zhao; Geoffrey R Oxnard; Lawrence H Schwartz
Journal:  JCO Clin Cancer Inform       Date:  2018-12

5.  BEAMing up personalized medicine: mutation detection in blood.

Authors:  Andrea L Richardson; J Dirk Iglehart
Journal:  Clin Cancer Res       Date:  2012-05-01       Impact factor: 12.531

Review 6.  Clinical potential of mass spectrometry-based proteogenomics.

Authors:  Bing Zhang; Jeffrey R Whiteaker; Andrew N Hoofnagle; Geoffrey S Baird; Karin D Rodland; Amanda G Paulovich
Journal:  Nat Rev Clin Oncol       Date:  2019-04       Impact factor: 66.675

7.  Modeling NSCLC progression: recent advances and opportunities available.

Authors:  Ahmed Abbas Suleiman; Lucia Nogova; Uwe Fuhr
Journal:  AAPS J       Date:  2013-02-13       Impact factor: 4.009

Review 8.  Epigenetics advancing personalized nanomedicine in cancer therapy.

Authors:  Shujun Liu
Journal:  Adv Drug Deliv Rev       Date:  2012-08-19       Impact factor: 15.470

Review 9.  Clinical trial designs incorporating predictive biomarkers.

Authors:  Lindsay A Renfro; Himel Mallick; Ming-Wen An; Daniel J Sargent; Sumithra J Mandrekar
Journal:  Cancer Treat Rev       Date:  2016-01-05       Impact factor: 12.111

10.  The Effect of Quercetin Nanosuspension on Prostate Cancer Cell Line LNCaP via Hedgehog Signaling Pathway.

Authors:  Nadia Mousavi; Shahrzad Rahimi; Hanane Emami; Amir Hossein Kazemi; Rana Mohammad Taghi Kashi; Ronak Heidarian
Journal:  Rep Biochem Mol Biol       Date:  2021-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.